The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•29 April 2026•

1 min read

Goldman Sachs Lowers Zimmer Biomet Price Target, Maintains Sell Rating

Key Facts

1Goldman Sachs adjusted its price target for Zimmer Biomet to $86 from $89.

2The bank maintained its Sell rating on the stock in its latest report.

Goldman Sachs has adjusted its price target for Zimmer Biomet (ZBH) downward to $86 from the previous $89. The investment bank maintained its Sell rating on the stock, signaling a cautious outlook on the medical device manufacturer's performance. This revision reflects updated analyst views regarding the company's prospects within the orthopedic reconstruction and traumatology sectors. The decision highlights potential headwinds that may limit the company's growth trajectory compared to its industry peers. Such a downgrade from a major financial institution typically exerts downward pressure on the stock's market valuation. Investors are now closely monitoring the firm's upcoming financial disclosures for signs of operational recovery.